{
    "id": 17229,
    "fullName": "FGFR2 - OFD1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-OFD1 results from the fusion of FGFR2 and OFD1 (PMID: 23558953), leading to activation of Fgfr downstream signaling and transformation in culture (PMID: 28416604). FGFR2-OFD1 has been identified in thyroid carcinoma (PMID: 23558953).",
            "references": [
                {
                    "id": 15175,
                    "pubMedId": 28416604,
                    "title": "Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416604"
                },
                {
                    "id": 4387,
                    "pubMedId": 23558953,
                    "title": "Identification of targetable FGFR gene fusions in diverse cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23558953"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - OFD1",
    "createDate": "01/25/2016",
    "updateDate": "06/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 8481,
                "geneSymbol": "OFD1",
                "terms": [
                    "OFD1",
                    "71-7A",
                    "CXorf5",
                    "JBTS10",
                    "RP23",
                    "SGBS2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 17164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-OFD1 in culture (PMID: 28416604).",
            "molecularProfile": {
                "id": 17515,
                "profileName": "FGFR2 - OFD1"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15175,
                    "pubMedId": 28416604,
                    "title": "Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416604"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4006,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in an endometrial cancer patient harboring FGFR2-BICC1 and FGFR2-OFD1 fusions (PMID: 26324363; NCT01703481).",
            "molecularProfile": {
                "id": 31774,
                "profileName": "FGFR2 - BICC1 FGFR2 - OFD1"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4363,
                    "pubMedId": 26324363,
                    "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324363"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17515,
            "profileName": "FGFR2 - OFD1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31774,
            "profileName": "FGFR2 - BICC1 FGFR2 - OFD1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}